356 related articles for article (PubMed ID: 25468994)
1. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.
Littlefield P; Liu L; Mysore V; Shan Y; Shaw DE; Jura N
Sci Signal; 2014 Dec; 7(354):ra114. PubMed ID: 25468994
[TBL] [Abstract][Full Text] [Related]
2. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
3. HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.
Choi BK; Cai X; Yuan B; Huang Z; Fan X; Deng H; Zhang N; An Z
Protein Cell; 2012 Oct; 3(10):781-9. PubMed ID: 22983903
[TBL] [Abstract][Full Text] [Related]
4. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
Jura N; Shan Y; Cao X; Shaw DE; Kuriyan J
Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21608-13. PubMed ID: 20007378
[TBL] [Abstract][Full Text] [Related]
5. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.
Collier TS; Diraviyam K; Monsey J; Shen W; Sept D; Bose R
J Biol Chem; 2013 Aug; 288(35):25254-25264. PubMed ID: 23843458
[TBL] [Abstract][Full Text] [Related]
6. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
[TBL] [Abstract][Full Text] [Related]
7. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.
Shi F; Telesco SE; Liu Y; Radhakrishnan R; Lemmon MA
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7692-7. PubMed ID: 20351256
[TBL] [Abstract][Full Text] [Related]
8. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
9. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
Shankaran H; Zhang Y; Tan Y; Resat H
PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23.
Liu L; Thaker TM; Freed DM; Frazier N; Malhotra K; Lemmon MA; Jura N
Structure; 2018 Feb; 26(2):270-281.e4. PubMed ID: 29358026
[TBL] [Abstract][Full Text] [Related]
11. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
[TBL] [Abstract][Full Text] [Related]
12. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
13. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells.
Zhang Y; Opresko L; Shankaran H; Chrisler WB; Wiley HS; Resat H
BMC Cell Biol; 2009 Oct; 10():78. PubMed ID: 19878579
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.
Banappagari S; Corti M; Pincus S; Satyanarayanajois S
J Biomol Struct Dyn; 2012; 30(5):594-606. PubMed ID: 22731912
[TBL] [Abstract][Full Text] [Related]
15. A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network.
Telesco SE; Shih AJ; Jia F; Radhakrishnan R
Mol Biosyst; 2011 Jun; 7(6):2066-80. PubMed ID: 21509365
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.
Dey P; Gadewal N; De A
Int J Biol Macromol; 2023 Jul; 242(Pt 2):124765. PubMed ID: 37156315
[TBL] [Abstract][Full Text] [Related]
17. Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine Kinases.
Keppel TR; Sarpong K; Murray EM; Monsey J; Zhu J; Bose R
J Biol Chem; 2017 Jan; 292(2):597-610. PubMed ID: 27872189
[TBL] [Abstract][Full Text] [Related]
18. Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
Jin P; Zhang J; Beryt M; Turin L; Brdlik C; Feng Y; Bai X; Liu J; Jorgensen B; Shepard HM
Mol Med; 2009; 15(1-2):11-20. PubMed ID: 19048033
[TBL] [Abstract][Full Text] [Related]
19. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
Umelo I; Noeparast A; Chen G; Renard M; Geers C; Vansteenkiste J; Giron P; De Wever O; Teugels E; De Grève J
Oncotarget; 2016 Jan; 7(3):3068-83. PubMed ID: 26689995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]